We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 02, 2020

Effect of Spironolactone on CV Function and Fibrosis in People at Increased Risk of Developing Heart Failure

European Heart Journal


Additional Info

European Heart Journal
The Effect of Spironolactone on Cardiovascular Function and Markers of Fibrosis in People at Increased Risk of Developing Heart Failure: The Heart 'OMics' in AGEing (HOMAGE) Randomized Clinical Trial
Eur Heart J 2020 Nov 20;[EPub Ahead of Print], JGF Cleland, JP Ferreira, B Mariottoni, P Pellicori, J Cuthbert, JAJ Verdonschot, J Petutschnigg, FZ Ahmed, F Cosmi, HP Brunner La Rocca, MA Mamas, AL Clark, F Edelmann, B Pieske, J Khan, K McDonald, P Rouet, JA Staessen, B Mujaj, A González, J Diez, M Hazebroek, S Heymans, R Latini, S Grojean, A Pizard, N Girerd, P Rossignol, TJ Collier, F Zannad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading